BioWorld

Jan. 24, 2002

EntreMed, Allergan Collaborate On Ophthalmic Uses Of Panzem

Allergan Inc. struck a five-year deal potentially worth more than $40 million with EntreMed Inc. to develop and commercialize the latter’s angiogenic inhibitor, Panzem, for ophthalmolic uses. Read More

Xenerex Enters Antibody Deal With Schering-Plough’s DNAX

3-D Structure Of Deadly Bacillus Anthracis Edema Factor Protein Reveals Drug-Finding Weak Spot

NeurogesX Raises $23M To Develop Products For Pain

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...